Table 4.

LncRNAs involved in tumor response to mAb-mediated immunotherapy.

LncRNA	Type of Cancer #	Drug	Ab Target	Effect	Resistance Mediators	Ref.
lnc-ATB	BC	Trastuzumab	EGFR	Induces resistance	ZEB1, ZNF-217, miR-200c	[132]
GAS5	BC	Trastuzumab	EGFR	Augmented response	miR21/ PTEN/ mTOR	[133]
SNHG14	HER2+ BC	Trastuzumab	EGFR	Induces resistance	Bcl-2/Bax	[134]
UCA1	CRC	Cetuximab	EGFR	Induces resistance	N/A	[135]
LINK-A	TNBC	Pembrolizumab	PD-1	Induces resistance	N/A	[84,136]
RP11-705C-15.3	NSCLC	PD-1 checkpoint inhibitors	PD-1	Induces resistance	N/A	[137]
RP11-291B-21.2	NSCLC BLCA	Durvalumab	PD-L1	Augmented response	N/A	[138]

Abbreviations used: IS, Immunosuppression; IM, Immunomodulation; N/A, not assessed; CTLs, Cytotoxic T lymphocytes; TILs, Tumor infiltrating lymphocytes; Tregs, Regulatory T cells; CCs, Cancer cells, DCs, Dendritic cells; PBMCs, Peripheral blood mononuclear cells; PD-1, Programmed cell death protein-1. ^# NCI-based TCGA-based abbreviations available online: https://gdc.cancer.gov/recources-tcga-users/tcga-code-tables/tcga-study-abbreviations (accessed on 13 October 2021): BC, Breast Cancer; CRC, Colorectal Cancer; NSCLC, Non-small cell lung cancer; TNBC, Triple negative breast cancer; BLCA, Bladder cancer.